Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast

Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on August 5, 2020 at 11:30 a.m. ET to discuss its Q2 2020 financial results and provide updates on its pipeline and business progress.

Rhea-AI Summary

Ionis Pharmaceuticals (NASDAQ: IONS) will host a live webcast on August 5, 2020 at 11:30 a.m. ET to discuss its Q2 2020 financial results and provide updates on its pipeline and business progress. This event will focus on the company's advancements in RNA-targeted drug discovery, highlighting their innovative antisense technology that addresses unmet medical needs.

Positive

• Leading position in RNA-targeted drug discovery.
• Robust pipeline with over 40 novel medicines under development.

Negative

• None.

Argus Session date unavailable

-0.62% session move Open Argus

Details

News Market Reaction – IONS

The recorded move for IONS in the trading session of this news was -0.62%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., July 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Wednesday, August 5^th at 11:30 a.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.

Interested parties may access the webcast at www.ionispharma.com. A webcast replay will be available for a limited time at the same address.

About Ionis Pharmaceuticals
As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis. Our sights are set on all the patients we have yet to reach with a pipeline of more than 40 novel medicines designed to potentially treat a broad range of diseases, including neurological, cardiovascular, infectious, and pulmonary diseases.

To learn more about Ionis visit www.ionispharma.com and follow us on twitter @ionispharma.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-to-hold-second-quarter-2020-financial-results-webcast-301097463.html

SOURCE Ionis Pharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ionis Pharmaceuticals announce its Q2 2020 financial results?

Ionis Pharmaceuticals will announce its Q2 2020 financial results on August 5, 2020, during a live webcast.

How can I access the Ionis Pharmaceuticals webcast?

The webcast for Ionis Pharmaceuticals can be accessed through their official website at www.ionispharma.com.

What is Ionis Pharmaceuticals known for?

Ionis Pharmaceuticals is known for its RNA-targeted drug discovery and has developed the first approved treatment for spinal muscular atrophy.

What is the significance of antisense technology in drug development?

Antisense technology is significant as it enables the treatment of diseases where other therapeutic approaches have failed, showcasing Ionis's innovative capabilities.